Compounds > terephthalamidine
Page last updated: 2024-11-07

terephthalamidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

terephthalamidine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID159756
CHEMBL ID1187958
SCHEMBL ID537030
MeSH IDM0137754

Synonyms (18)

Synonym
1,4-benzenedicarboximidamide
terephthalamidine
15411-54-8
1,4-diamidinobenzene
benzene-1,4-dicarboximidamide
AKOS004903531
CHEMBL1187958
SCHEMBL537030
mfcd01108407
DTXSID10165538
terephthalamidin
terephthalimidamide
FT-0700960
CS-0014259
EN300-817875
benzdiamidine
benzene-1,4-dicarboxamidine
A937483

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis by HPLC was performed in all patients during their first course."( A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.
Campbell, L; Clark, GM; De La Cruz, P; Eckardt, JR; Fields, SM; Hilsenbeck, SG; Kuhn, JG; New, P; Rodriguez, GI; Von Hoff, DD; Weiss, G, 1998)		0.57

Bioavailability

ExcerptReferenceRelevance
"The limitations of current therapies for the treatment of iron overload or radioisotope contamination have stimulated efforts to develop new orally bioavailable iron and actinide chelators."( Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators.
Abergel, RJ; Raymond, KN, 2011)		0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's2 (18.18)18.2507
2000's6 (54.55)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.06 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews1 (9.09%)6.00%
Case Studies1 (9.09%)4.05%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
triaziquone
Triaziquone: Alkylating antineoplastic agent used mainly for ovarian tumors. It is toxic to skin, gastrointestinal tract, bone marrow and kidneys.. triaziquone : A member of the class of 1,4-benzoquinones that is 1,4-benzoquinone in which three of the ring hydrogens are replaced by aziridin-1-yl groups.		1.96101,4-benzoquinones;
aziridines		alkylating agent;
antineoplastic agent
glycosides
[no description available]		2.0510
mitindomide
mitindomide: structure given in first source		1.9610
3-deazauridine
3-Deazauridine: 4-Hydroxy-1-(beta-D-ribofuranosyl)-2-pyridinone. Analog of uridine lacking a ring-nitrogen in the 3-position. Functions as an antineoplastic agent.		1.9610N-glycosyl compound
ConditionIndicatedRelationship StrengthStudiesTrials
Injuries, Maxillofacial
[description not available]		02.0510
Linear Skull Fracture
[description not available]		02.0510
Blow Out Fracture
[description not available]		02.0510
Maxillary Fractures
Fractures of the upper jaw.		02.0510
Zygomatic Fractures
Fractures of the zygoma.		02.0510
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.3811
Benign Neoplasms
[description not available]		03.3811
Weight Reduction
[description not available]		03.3811
Anorexia
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.		03.3811
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.3811
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.3811
Weight Loss
Decrease in existing BODY WEIGHT.		03.3811